Aged
G. Novak, Fox, N., Clegg, S., Nielsen, C., Einstein, S., Lu, Y., Tudor, I. Cristina, Gregg, K., Di, J., Collins, P., Wyman, B. T., Yuen, E., Grundman, M., H Brashear, R., and Liu, E.,
“Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease.”,
J Alzheimers Dis, vol. 49, no. 4, pp. 1123-34, 2016.
Alzheimer Disease
G. Novak, Fox, N., Clegg, S., Nielsen, C., Einstein, S., Lu, Y., Tudor, I. Cristina, Gregg, K., Di, J., Collins, P., Wyman, B. T., Yuen, E., Grundman, M., H Brashear, R., and Liu, E.,
“Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease.”,
J Alzheimers Dis, vol. 49, no. 4, pp. 1123-34, 2016.
Antibodies, Monoclonal, Humanized
G. Novak, Fox, N., Clegg, S., Nielsen, C., Einstein, S., Lu, Y., Tudor, I. Cristina, Gregg, K., Di, J., Collins, P., Wyman, B. T., Yuen, E., Grundman, M., H Brashear, R., and Liu, E.,
“Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease.”,
J Alzheimers Dis, vol. 49, no. 4, pp. 1123-34, 2016.
Apolipoprotein E4
G. Novak, Fox, N., Clegg, S., Nielsen, C., Einstein, S., Lu, Y., Tudor, I. Cristina, Gregg, K., Di, J., Collins, P., Wyman, B. T., Yuen, E., Grundman, M., H Brashear, R., and Liu, E.,
“Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease.”,
J Alzheimers Dis, vol. 49, no. 4, pp. 1123-34, 2016.
Brain
G. Novak, Fox, N., Clegg, S., Nielsen, C., Einstein, S., Lu, Y., Tudor, I. Cristina, Gregg, K., Di, J., Collins, P., Wyman, B. T., Yuen, E., Grundman, M., H Brashear, R., and Liu, E.,
“Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease.”,
J Alzheimers Dis, vol. 49, no. 4, pp. 1123-34, 2016.
Double-Blind Method
G. Novak, Fox, N., Clegg, S., Nielsen, C., Einstein, S., Lu, Y., Tudor, I. Cristina, Gregg, K., Di, J., Collins, P., Wyman, B. T., Yuen, E., Grundman, M., H Brashear, R., and Liu, E.,
“Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease.”,
J Alzheimers Dis, vol. 49, no. 4, pp. 1123-34, 2016.
Female
G. Novak, Fox, N., Clegg, S., Nielsen, C., Einstein, S., Lu, Y., Tudor, I. Cristina, Gregg, K., Di, J., Collins, P., Wyman, B. T., Yuen, E., Grundman, M., H Brashear, R., and Liu, E.,
“Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease.”,
J Alzheimers Dis, vol. 49, no. 4, pp. 1123-34, 2016.
Heterozygote
G. Novak, Fox, N., Clegg, S., Nielsen, C., Einstein, S., Lu, Y., Tudor, I. Cristina, Gregg, K., Di, J., Collins, P., Wyman, B. T., Yuen, E., Grundman, M., H Brashear, R., and Liu, E.,
“Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease.”,
J Alzheimers Dis, vol. 49, no. 4, pp. 1123-34, 2016.
Humans
G. Novak, Fox, N., Clegg, S., Nielsen, C., Einstein, S., Lu, Y., Tudor, I. Cristina, Gregg, K., Di, J., Collins, P., Wyman, B. T., Yuen, E., Grundman, M., H Brashear, R., and Liu, E.,
“Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease.”,
J Alzheimers Dis, vol. 49, no. 4, pp. 1123-34, 2016.
Least-Squares Analysis
G. Novak, Fox, N., Clegg, S., Nielsen, C., Einstein, S., Lu, Y., Tudor, I. Cristina, Gregg, K., Di, J., Collins, P., Wyman, B. T., Yuen, E., Grundman, M., H Brashear, R., and Liu, E.,
“Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease.”,
J Alzheimers Dis, vol. 49, no. 4, pp. 1123-34, 2016.
Magnetic Resonance Imaging
G. Novak, Fox, N., Clegg, S., Nielsen, C., Einstein, S., Lu, Y., Tudor, I. Cristina, Gregg, K., Di, J., Collins, P., Wyman, B. T., Yuen, E., Grundman, M., H Brashear, R., and Liu, E.,
“Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease.”,
J Alzheimers Dis, vol. 49, no. 4, pp. 1123-34, 2016.
Male
G. Novak, Fox, N., Clegg, S., Nielsen, C., Einstein, S., Lu, Y., Tudor, I. Cristina, Gregg, K., Di, J., Collins, P., Wyman, B. T., Yuen, E., Grundman, M., H Brashear, R., and Liu, E.,
“Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease.”,
J Alzheimers Dis, vol. 49, no. 4, pp. 1123-34, 2016.
Nootropic Agents
G. Novak, Fox, N., Clegg, S., Nielsen, C., Einstein, S., Lu, Y., Tudor, I. Cristina, Gregg, K., Di, J., Collins, P., Wyman, B. T., Yuen, E., Grundman, M., H Brashear, R., and Liu, E.,
“Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease.”,
J Alzheimers Dis, vol. 49, no. 4, pp. 1123-34, 2016.
Organ Size
G. Novak, Fox, N., Clegg, S., Nielsen, C., Einstein, S., Lu, Y., Tudor, I. Cristina, Gregg, K., Di, J., Collins, P., Wyman, B. T., Yuen, E., Grundman, M., H Brashear, R., and Liu, E.,
“Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease.”,
J Alzheimers Dis, vol. 49, no. 4, pp. 1123-34, 2016.
Severity of Illness Index
G. Novak, Fox, N., Clegg, S., Nielsen, C., Einstein, S., Lu, Y., Tudor, I. Cristina, Gregg, K., Di, J., Collins, P., Wyman, B. T., Yuen, E., Grundman, M., H Brashear, R., and Liu, E.,
“Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease.”,
J Alzheimers Dis, vol. 49, no. 4, pp. 1123-34, 2016.
Treatment Outcome
G. Novak, Fox, N., Clegg, S., Nielsen, C., Einstein, S., Lu, Y., Tudor, I. Cristina, Gregg, K., Di, J., Collins, P., Wyman, B. T., Yuen, E., Grundman, M., H Brashear, R., and Liu, E.,
“Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease.”,
J Alzheimers Dis, vol. 49, no. 4, pp. 1123-34, 2016.